April 13, 2026 — The global neoantigen cancer vaccine market is witnessing significant growth, fueled by advancements in personalized medicine, increasing cancer prevalence, and rising investments in oncology research. The market, valued at USD 377.53 million in 2024, is projected to grow from USD 434.16 million in 2025 to USD 1,328.10 million by 2033, expanding...